Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 8/20 | 0.69 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18284733 | 0.90 | SLC18A3 (0.60) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL4473029 | 0.90 | SLC18A3 (0.60) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL4459123 | 0.90 | SLC18A3 (0.60) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL2965273 | 0.87 | SLC18A3 (0.81) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL27709432 | 0.86 | CYP2D6 (0.65) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL22055105 | 0.84 | SLC18A3 (0.66) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL30563652 | 0.83 | SLC18A3 (0.96) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL17850380 | 0.83 | SLC18A3 (0.53) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL31222854 | 0.83 | SLC18A3 (0.47) | SLC18A3GRIN2BCYP2D6CYP2C19CYP2C9 | |
| SCHEMBL7888827 | 0.81 | SLC18A3 (1.00) | SLC18A3GRIN2BCYP2D6CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302465-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016197009-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-08 | — | — | WO | disclosed |
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | SLC18A3 3509/4885GRIN2B 3868/4885CYP2D6 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.